The effect of Ganoderm on glycemic control in diabetic patients

Evaluation of the effect of Ganoderm lucidum (with usual diabetes medications) on blood glucose control in type 2 diabetic patients: A placebo-controlled double-blind clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200716048118N1

Enrollment

Registered

2020-11-25

Start date

2020-10-22

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type 2. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: In this group patients take their oral diabetes medications without any changes and in addition, they receive treatment with ganoderma including one ganoderma capsu

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Type 2 Diabetic patients age 30-70 HbA1c 8-10%

Exclusion criteria

Exclusion criteria: liver failure renal failure pregnant women lactating women insulin therapy

Design outcomes

Primary

Measure	Time frame
Blood glucose. Timepoint: Begging and at after 12 weeks of treatment. Method of measurement: Biochemical method and autoanalyser.	—

Secondary

Measure	Time frame
Cholesterol Total. Timepoint: Triglyceride. Method of measurement: Biochemistry- Calorimetry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Bandarian

Tehran University of Medical Sciences

fbandarian@yahoo.com+98 21 8833 8742

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026